Hello Turtle,
I just had a chance to listen to the call. Spana did indeed say "very shortly", but on the recent previous call he said "two to three months", so frankly, I have no idea when results will be available and suspect he doesn't, either.
It would be terrific to hear some positive results before options expiration. I agree he seemed to be trying to telegraph positive results with statements such as "we're talking about phase 3 for the first time", but we'll see.
I didn't go for AOM or SPPI, but I did pick up NUVO previously on your recommendation, so thanks again! I'm still holding ARNA and still expect great things. It's too bad the MRK drug didn't fly, but we had clues it wasn't going well; they changed the drug description in press releases and in their website to "Niacin" from a novel agonist, which suggested to me the drug was no more efficacious than niacin. I commented on this previously. The big potential remains in APD356 (lorcaserin) and '668, with some interest in '125 too. They have outlined an ambitious phase 3 program for lorcaserin and I wish they'd start the safety program already, as that's going to be the rate limiting step on the road to the NDA.
As we discussed previously, I did pick up a small basket of cheap microcap oncology stocks to hold for a couple of years. These include POTP, GENT, ARQL and EXEL. All are at least in phase 2, with two of them in phase 3. I recently doubled down on POTP.
The next 18 months are going to be interesting for our portfolios...
RE42 |
